FLT3 inhibitor maintenance after allogeneic transplantation is associated with improved survival in FLT3-mutated AML: MRD-stratified evidence from an updated meta-analysis.

IF 5.1 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2026-09-21 DOI:10.1038/s41409-026-03049-y

Abdulrahim Mohammed Basendwah, Akihiro Miyashita, Henri Fero, Mohammed Alasmari, Fahad Alabbas

引用次数: 0

查看原文本刊更多论文

异体移植后维持FLT3抑制剂与FLT3突变AML患者生存率提高相关：来自最新荟萃分析的mrd分层证据

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.